BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 17911582)

  • 1. The role of apoptosis in the ameliorating effects of a CDR1-based peptide on lupus manifestations in a mouse model.
    Sharabi A; Luger D; Ben-David H; Dayan M; Zinger H; Mozes E
    J Immunol; 2007 Oct; 179(8):4979-87. PubMed ID: 17911582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The suppression of murine lupus by a tolerogenic peptide involves foxp3-expressing CD8 cells that are required for the optimal induction and function of foxp3-expressing CD4 cells.
    Sharabi A; Mozes E
    J Immunol; 2008 Sep; 181(5):3243-51. PubMed ID: 18713995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A tolerogenic peptide down-regulates mature B cells in bone marrow of lupus-afflicted mice by inhibition of interleukin-7, leading to apoptosis.
    Ben-David H; Sharabi A; Parameswaran R; Zinger H; Mozes E
    Immunology; 2009 Oct; 128(2):245-52. PubMed ID: 19740381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The inhibition of autoreactive T cell functions by a peptide based on the CDR1 of an anti-DNA autoantibody is via TGF-beta-mediated suppression of LFA-1 and CD44 expression and function.
    Sela U; Mauermann N; Hershkoviz R; Zinger H; Dayan M; Cahalon L; Liu JP; Mozes E; Lider O
    J Immunol; 2005 Dec; 175(11):7255-63. PubMed ID: 16301630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The negative regulators Foxj1 and Foxo3a are up-regulated by a peptide that inhibits systemic lupus erythematosus-associated T cell responses.
    Sela U; Dayan M; Hershkoviz R; Cahalon L; Lider O; Mozes E
    Eur J Immunol; 2006 Nov; 36(11):2971-80. PubMed ID: 17051618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical amelioration of murine lupus by a peptide based on the complementarity determining region-1 of an autoantibody and by cyclophosphamide: similarities and differences in the mechanisms of action.
    Sharabi A; Azulai H; Sthoeger ZM; Mozes E
    Immunology; 2007 Jun; 121(2):248-57. PubMed ID: 17346282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amelioration of brain pathology and behavioral dysfunction in mice with lupus following treatment with a tolerogenic peptide.
    Lapter S; Marom A; Meshorer A; Elmann A; Sharabi A; Vadai E; Neufeld A; Sztainberg Y; Gil S; Getselter D; Chen A; Mozes E
    Arthritis Rheum; 2009 Dec; 60(12):3744-54. PubMed ID: 19950283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-regulation of stromal cell-derived factor-1alpha-induced T cell chemotaxis by a peptide based on the complementarity-determining region 1 of an anti-DNA autoantibody via up-regulation of TGF-beta secretion.
    Sela U; Hershkoviz R; Cahalon L; Lider O; Mozes E
    J Immunol; 2005 Jan; 174(1):302-9. PubMed ID: 15611253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel tolerogenic peptide, hCDR1, for the specific treatment of systemic lupus erythematosus.
    Mozes E; Sharabi A
    Autoimmun Rev; 2010 Nov; 10(1):22-6. PubMed ID: 20659591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The tolerogenic peptide hCDR1 downregulates pathogenic cytokines and apoptosis and upregulates immunosuppressive molecules and regulatory T cells in peripheral blood mononuclear cells of lupus patients.
    Sthoeger ZM; Sharabi A; Dayan M; Zinger H; Asher I; Sela U; Mozes E
    Hum Immunol; 2009 Mar; 70(3):139-45. PubMed ID: 19280712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bcl-xL is required for the development of functional regulatory CD4 cells in lupus-afflicted mice following treatment with a tolerogenic peptide.
    Sharabi A; Lapter S; Mozes E
    J Autoimmun; 2010 Mar; 34(2):87-95. PubMed ID: 19596183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A peptide that ameliorates lupus up-regulates the diminished expression of early growth response factors 2 and 3.
    Sela U; Dayan M; Hershkoviz R; Lider O; Mozes E
    J Immunol; 2008 Feb; 180(3):1584-91. PubMed ID: 18209054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amelioration of murine lupus by a peptide, based on the complementarity determining region-1 of an autoantibody as compared to dexamethasone: different effects on cytokines and apoptosis.
    Sharabi A; Haviv A; Zinger H; Dayan M; Mozes E
    Clin Immunol; 2006 May; 119(2):146-55. PubMed ID: 16503419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The tolerogenic peptide, hCDR1, down-regulates the expression of interferon-α in murine and human systemic lupus erythematosus.
    Sthoeger Z; Zinger H; Sharabi A; Asher I; Mozes E
    PLoS One; 2013; 8(3):e60394. PubMed ID: 23555966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A peptide based on the complementarity-determining region 1 of an autoantibody ameliorates lupus by up-regulating CD4+CD25+ cells and TGF-beta.
    Sharabi A; Zinger H; Zborowsky M; Sthoeger ZM; Mozes E
    Proc Natl Acad Sci U S A; 2006 Jun; 103(23):8810-5. PubMed ID: 16735466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered gene expression in mice with lupus treated with edratide, a peptide that ameliorates the disease manifestations.
    Elmann A; Sharabi A; Dayan M; Zinger H; Ophir R; Mozes E
    Arthritis Rheum; 2007 Jul; 56(7):2371-81. PubMed ID: 17599765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of dendritic cells in the mechanism of action of a peptide that ameliorates lupus in murine models.
    Sela U; Sharabi A; Dayan M; Hershkoviz R; Mozes E
    Immunology; 2009 Sep; 128(1 Suppl):e395-405. PubMed ID: 19040426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): immunomodulation of gene expression.
    Sthoeger ZM; Sharabi A; Molad Y; Asher I; Zinger H; Dayan M; Mozes E
    J Autoimmun; 2009 Aug; 33(1):77-82. PubMed ID: 19346102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B-cell activating factor (BAFF) plays a role in the mechanism of action of a tolerogenic peptide that ameliorates lupus.
    Parameswaran R; Ben David H; Sharabi A; Zinger H; Mozes E
    Clin Immunol; 2009 May; 131(2):223-32. PubMed ID: 19188092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A tolerogenic peptide that induces suppressor of cytokine signaling (SOCS)-1 restores the aberrant control of IFN-gamma signaling in lupus-affected (NZB x NZW)F1 mice.
    Sharabi A; Sthoeger ZM; Mahlab K; Lapter S; Zinger H; Mozes E
    Clin Immunol; 2009 Oct; 133(1):61-8. PubMed ID: 19631585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.